Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab dosed the first patient in NOV-ERA, a global Phase 2b study of ontunisertib in fibrostenosing Crohn's disease, expected to enroll roughly 320 patients. The randomized, placebo-controlled, dose-ranging trial tests 400 mg, 200 mg, and 100 mg BID doses over 52 weeks, with endoscopic passability at Week 24 as the primary endpoint.
Key figures
- Drug Name
- ontunisertib (AGMB-129)
- Phase Of Trial
- Phase 2b
- Planned enrollment
- 320
- Milestone payment eur
- €7 million
- Treatment duration weeks
- 52
- Milestones paid to date eur
- €10 million
- Total potential milestones eur
- €20 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.